Thyl Up-regulates fasL expression in lung myofibroblasts via src family kinases

American Journal of Respiratory Cell and Molecular Biology

Volumn 40, Issue 2, 2009, Pages 231-238

  Cohen, Pazit Y ^a   Breuer, Raphael ^a,b,c   Wallach Dayan, Shulamit B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Fasl; Myofibroblast; Src; Thy 1

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BLEOMYCIN; FAS LIGAND; GAMMA INTERFERON; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; FYN PROTEIN, HUMAN; FYN PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL SURFACE; CONTROLLED STUDY; LUNG FIBROBLAST; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; HUMAN; METABOLISM; MYOBLAST; PHYSIOLOGY;

MUS;

ANIMALS; ANTIGENS, THY-1; ANTIVIRAL AGENTS; FAS LIGAND PROTEIN; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; MALE; MICE; MYOBLASTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FYN; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 59149084958     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0348OC     Document Type: Article

References (49)

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
2. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-148.
3. Kuwano K, Miyazaki H, Hagimoto N, Kawasaki M, Fujita M, Kunitake R, Kaneko Y, Hara N. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am J Respir Cell Mol Biol 1999;20:53-60.
4. Oshimi Y, Oda S, Honda Y, Nagata S, Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 1996;157:2909-2915.
5. 5.Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995;154:3806-3813.
6. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
7. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001;7:271-274.
8. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004;122:44-50.
9. Saitoh A, Kawanabe T, Weidong H, Kayagaki N, Kawamura T, Yagita H, Okumura K, Shimada S. Selective upregulation of fibroblast Fas ligand expression, and prolongation of Fas/Fas ligand-mediated skin allograft survival, by retinoic acid: the skin as a retinoide-inducible immune privilege site. J Invest Dermatol 2000;115:154-161.
10. Kavurma MM, Khachigian LM. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 2003;10:36-44.
11. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-1213.
12. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36.
13. Shangary S, Lerner EC, Zhan Q, Corey SJ, Smithgall TE, Baskaran R. Lyn regulates the cell death response to ultraviolet radiation through c-Jun N terminal kinase-dependent Fas ligand activation. Exp Cell Res 2003;289:67-76.
14. Choi C, Park JY, Lee J, Lim JH, Shin EC, Ahn YS, Kim CH, Kim SJ, Kim JD, Choi IS, et al. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J Immunol 1999;162:1889-1895.
15. Chow WA, Fang JJ, Yee JK. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol 2000;164:3512-3518.
16. Kojima H, Toda M, Sitkovsky MV. Comparison of Fas- versus perforin-mediated pathways of cytotoxicity in TCR- and Thy-1-activated murine T cells. Int Immunol 2000;12:365-374.
17. Williams AF, Tse AG. A glycophospholipid covalently attached to the C-terminus of the Thy-1 glycoprotein. Biosci Rep 1985;5:999-1005.
18. Haeryfar SM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker. J Immunol 2004;173:3581-3588.
19. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006;20:1045-1054.
20. Haeryfar SM, Hoskin DW. Selective pharmacological inhibitors reveal differences between Thy-1- and T cell receptor-mediated signal trans- duction in mouse T lymphocytes. Int Immunopharmacol 2001;1:689-698.
21. Garnett D, Barclay AN, Carmo AM, Beyers AD. The association of the protein tyrosine kinases p56lck and p60fyn with the glycosyl phosphatidylinositol-anchored proteins Thy-1 and CD48 in rat thymocytes is dependent on the state of cellular activation. Eur J Immunol 1993; 23:2540-2544.
22. Narisawa-Saito M, Yamanashi Y, Morioka T, Oite T, Shimizu F. Thy-1 molecule associates with protein tyrosine kinase(s) in rat mesangial cells. Clin Exp Immunol 1996;106:86-90.
23. Gonzalez-Garcia A, R-Borlado L, Leonardo E, Merida I, Martinez AC, Carrera AC. Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells. JImmunol 1997;158: 4104-4112.
24. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994;72:283-292.
25. Phipps RP, Penney DP, Keng P, Quill H, Paxhia A, Derdak S, Felch ME. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am J Respir Cell Mol Biol 1989;1:65-74.
26. Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta 2006;1763:991-999.
27. 27.Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. Am J Respir Cell Mol Biol 2007;36:226-235.
28. Barker TH, Grenett HE, MacEwen MW, Tilden SG, Fuller GM, Settleman J, Woods A, Murphy-Ullrich J, Hagood JS. Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Exp Cell Res 2004;295:488-496.
29. Golan-Gerstl R, Wallach-Dayan SB, Amir G, Breuer R. Epithelial cell apoptosis by fas ligand-positive myofibroblasts in lung fibrosis. Am J Respir Cell Mol Biol 2007;36:270-275.
30. Wallach-Dayan SB, Golan-Gerstl R, Breuer R. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc Natl Acad Sci USA 2007;104:20460-20465.
31. Durieu I, Amsellem C, Paulin C, Chambe MT, Bienvenu J, Bellon G, Pacheco Y. Fas and Fas ligand expression in cystic fibrosis airway epithelium. Thorax 1999;54:1093-1098.
32. Saalbach A, Haustein UF, Anderegg U. A ligand of human thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated thy-1-positive microvascular endo- thelial cells and fibroblasts. J Invest Dermatol 2000;115:882-888.
33. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002;83:111-119.
34. Fesik SW. Insights into programmed cell death through structural biology. Cell 2000;103:273-282.
35. French LE, Tschopp J. Constitutive Fas ligand expression in several non- lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt 1996;97:156-160.
36. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 1999;5:90-96.
37. Desbarats J, Duke RC, Newell MK. Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 1998;4:1377-1382.
38. Suzuki I, Fink PJ. Maximal proliferation of cytotoxic T lymphocyte srequires reverse signaling through Fas ligand. J Exp Med 1998;187: 123-128.
39. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-441.
40. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003;14:53-66.
41. Rege TA, Pallero MA, Gomez C, Grenett HE, Murphy-Ullrich JE, Hagood JS. Thy-1, via its GPI anchor, modulates Src family kinase and focal adhesion kinase phosphorylation and subcellular localization, and fibroblast migration, in response to thrombospondin-1/hep I. Exp Cell Res 2006;312:3752-3767.
42. Anel A, Buferne M, Boyer C, Schmitt-Verhulst AM, Golstein P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur J Immunol 1994;24:2469-2476.
43. Wasem C, Frutschi C, Arnold D, Vallan C, Lin T, Green DR, Mueller C, Brunner T. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J Immunol 2001;167:2936-2941.
44. Blott EJ, Bossi G, Clark R, Zvelebil M, Griffiths GM. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci 2001;114:2405-2416.
45. Zuccato E, Blott EJ, Holt O, Sigismund S, Shaw M, Bossi G, Griffiths GM. Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. J Cell Sci 2007;120:191-199.
46. King TE, Schwarz MI. Idiopathic interstitial pneumonias. In: Murray JF, Nadel JA, editors. Textbook of respiratory medicine, 3rd ed. Philadelphia: W.B. Saunders Company; 2000. pp. 1671-1690.
47. Sulavik SB. A clinician's view. In: Phan SH, Thrall RS, editors. Pulmonary fibrosis: lung biology in health and disease. New York: Marcel Dekker; 1995. pp. 1-58.
48. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122:286S- 289S.
49. Derdak S, Penney DP, Keng P, Felch ME, Brown D, Phipps RP. Differential collagen and fibronectin production by Thy 1 + and Thy 1- lung fibroblast subpopulations. Am J Physiol 1992;263:L283-L290.